Corcept's Lifyorli Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer

Data demonstrate a 35% reduction in risk of death; Lifyorli added to NCCN Guidelines as preferred regimen

Apr. 13, 2026 at 4:53am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the intricate internal structures of an ovary, conceptually representing the clinical advances in treating ovarian cancer.The breakthrough Lifyorli treatment regimen aims to overcome the challenges of platinum-resistant ovarian cancer by modulating the effects of the hormone cortisol.Redwood City Today

Corcept Therapeutics presented final overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli (relacorilant) combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. The data, published simultaneously in The Lancet, showed Lifyorli plus nab-paclitaxel reduced the risk of death by 35% compared to nab-paclitaxel alone. Lifyorli, the first FDA-approved selective glucocorticoid receptor antagonist, has now been added to NCCN Guidelines as a preferred regimen for this patient population.

Why it matters

Patients with platinum-resistant ovarian cancer have limited treatment options, so the significant survival benefit demonstrated by the Lifyorli combination represents an important new standard of care. The addition of this regimen to NCCN Guidelines underscores its clinical value in addressing this devastating disease.

The details

The ROSELLA trial met its dual primary endpoints of overall and progression-free survival. Patients treated with Lifyorli plus nab-paclitaxel experienced a 35% reduction in the risk of death and a 30% reduction in the risk of disease progression compared to nab-paclitaxel alone. The combination was well-tolerated, with adverse events comparable to the nab-paclitaxel monotherapy arm.

  • Lifyorli, in combination with nab-paclitaxel, was approved by the FDA in March 2026.
  • The ROSELLA trial data were presented at the 2026 SGO Annual Meeting and published simultaneously in The Lancet.

The players

Corcept Therapeutics Incorporated

A commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.

Alexander B. Olawaiye, M.D.

Professor and Vice Chair of Diversity and Inclusion at Magee-Women's Hospital of the University of Pittsburgh, Principal Investigator in the ROSELLA trial, SGO presenter and Lancet publication author.

Domenica Lorusso, M.D., Ph.D.

Director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio X in Milan, and Full Professor of Obstetrics and Gynaecology at Humanitas University, Pieve Emanuele, Lancet publication senior author and European Network of Gynaecological Oncological Trial groups (ENGOT) investigator in the ROSELLA trial.

Bill Guyer, PharmD

Corcept's Chief Development Officer.

Lifyorli

The first FDA-approved selective glucocorticoid receptor antagonist, approved in combination with nab-paclitaxel for the treatment of adults with platinum-resistant ovarian cancer.

Got photos? Submit your photos here. ›

What they’re saying

“The safety and efficacy findings from ROSELLA are remarkable. They give hope to patients and oncologists now that we have a new preferred regimen in this devastating and difficult-to-treat cancer.”

— Alexander B. Olawaiye, M.D., Professor and Vice Chair of Diversity and Inclusion at Magee-Women's Hospital of the University of Pittsburgh, Principal Investigator in the ROSELLA trial, SGO presenter and Lancet publication author

“Patients with platinum-resistant ovarian cancer need more good treatment options. Relacorilant provides one. It significantly extends overall survival, with very little added toxicity. This regimen is firmly positioned as a new standard-of-care treatment for patients in the United States. We anticipate regulatory approval in Europe soon.”

— Domenica Lorusso, M.D., Ph.D., Director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio X in Milan, and Full Professor of Obstetrics and Gynaecology at Humanitas University, Pieve Emanuele, Lancet publication senior author and European Network of Gynaecological Oncological Trial groups (ENGOT) investigator in the ROSELLA trial

“ROSELLA's positive findings affirm our confidence that selective glucocorticoid receptor (GR) antagonists, such as relacorilant, may help treat any patient whose tumor type expresses the GR. With our recent FDA approval, we are now focused on delivering this therapy to patients and continuing cortisol modulation research in solid tumors that express GR across many different treatment settings.”

— Bill Guyer, PharmD, Corcept's Chief Development Officer

What’s next

Corcept has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for relacorilant to treat patients with platinum-resistant ovarian cancer.

The takeaway

The significant survival benefit and favorable safety profile of the Lifyorli plus nab-paclitaxel regimen, combined with its addition to NCCN Guidelines, establish it as a new standard of care for patients with platinum-resistant ovarian cancer, providing a much-needed new treatment option for this devastating disease.